表紙
市場調查報告書

關鍵意見領袖 (KOL)的見解:Ustekinumab臨床實驗資料

KOL Perceptions of Ustekinumab Data Presented at ACR 2017

出版商 GlobalData 商品編碼 721707
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
關鍵意見領袖 (KOL)的見解:Ustekinumab臨床實驗資料 KOL Perceptions of Ustekinumab Data Presented at ACR 2017
出版日期: 2018年06月26日內容資訊: 英文 30 Pages
簡介

本報告彙整產業關鍵意見領袖 (KOL) 的訪談調查結果,提供美國風濕學會主辦的「ARC 2017」所發表的Ustekinumab迄今的臨床實驗成果,及市場上的接受度,風濕藥上今後的利用·普及預測等相關資料。

目錄

  • 摘要整理
  • 背景情況
  • 研究小組組成
  • 調查結果及其意義

附錄

目錄
Product Code: GDHC032SP

This KOL Insight briefing focuses on perceptions of Ustekinumab Data Presented at ACR 2017.

The briefing includes analysis of KOL opinion on the following topic areas -

  • Perception of ustekinumab's Phase II efficacy data in SLE
  • Views on ustekinumab demonstrating significant efficacy at Week 24 in SLE
  • Ustekinumab's Phase II CLASI data in SLE
  • Ustekinumab's Phase II safety data in SLE
  • Impact of ustekinumab data in other indications on opinion of ustekinumab in SLE
  • Endpoints used in the Phase II ustekinumab trial in SLE
  • Anticipated future use of ustekinumab in SLE
  • Ideal additional endpoints or data for future ustekinumab trials in lupus

Key Highlights

  • Most KOLs had a positive opinion of ustekinumab's efficacy in SLE and highlighted that it appears to have a better response rate vs. belimumab
  • KOLs were broadly impressed with ustekinumab's CLASI data, and expect it to encourage ustekinumab uptake in lupus skin manifestations
  • Most KOLs had a positive view of ustekinumab's safety, but concerns were raised regarding the small patient population in the Phase II trial.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)
  • In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based
  • Interviews performed in December 2017.

Reasons to buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "Ustekinumab Data Presented at ACR 2017"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Table of Contents

  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications

Appendix

Back to Top